The activation of the PD-1/PD-L1 pathway results in T cell exhaustion, diminishing the ability of the immune system to attack tumor cells, thereby facilitating prostate cancer cell growth and dissemination under endocrine therapy [42]. Here, PDCD1 is linked to neoplasm.